Previous research by Fang et al., (2014) had shown that GSK J4 treatment reduces the expression of stemness genes, i.e., SOX2, Nanog, and OCT4 in breast cancer stem cells; however, they did not present direct evidence that KDM6B occupies the promoter of these genes in cancer cells. This evidence concerns the gene KDM6B and breast cancer.